Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Mar;143(3):242-247.
doi: 10.1111/ane.13355. Epub 2020 Oct 22.

Carbamazepine versus levetiracetam in epilepsy due to neurocysticercosis

Akhil P Santhosh  1 , Manoj Kumar Goyal  2 , Manish Modi  2 , Parampreet S Kharbanda  2 , Chirag K Ahuja  3 , Naresh Tandyala  2 , Nandita Prabhat  2 , Rajveer Singh  2 , Sahil Mehta  2 , Karthik Vinay Mahesh  2
Affiliations
Randomized Controlled Trial

Carbamazepine versus levetiracetam in epilepsy due to neurocysticercosis

Akhil P Santhosh et al. Acta Neurol Scand. 2021 Mar.

Abstract

Background: The choice of antiepileptic drug (AED) in newly diagnosed neurocysticercosis (NCC) patients with epilepsy continues to be arbitrary. We compared efficacy and side effect profile of levetiracetam (LEV) and carbamazepine (CBZ) for the treatment of seizures in newly diagnosed patients with NCC.

Patients and methods: This was an open-labeled randomized comparative monotherapy study including newly diagnosed drug naïve patients of NCC (n = 99) presenting with seizures who were randomized in 1:1 ratio using computed generated numbers. All patients were followed up for at least six months after start of treatment. The primary outcome measure was seizure control over six months following start of AEDs.

Results: Fifteen (15.2%) patients [CBZ- 4(8.2%); LEV- 11(22%)] developed recurrence of seizures. A trend (p = 0.09) was found toward better control of seizures in CBZ compared to LEV. Two (4%) patients in LEV group and 17 (34.6%) patients in CBZ group developed drug-related minor side effects (p < 0.0001). Three patients in CBZ group needed discontinuation of therapy due to skin rash. Eleven patients who relapsed while on LEV did not have any recurrence of seizures after switching over to CBZ. Out of 3 patients who relapsed while receiving CBZ and were changed to LEV, two developed seizures during follow-up.

Conclusion: CBZ and LEV could be used as alternatives in newly diagnosed patients of NCC at the behest of minor side effects in the CBZ group.

Keywords: carbamazepine; epilepsy; levetiracetam; neurocysticercosis.

PubMed Disclaimer

References

REFERENCES

    1. Del Brutto OH, Rajshekhar V, White AC, et al. Proposed diagnostic criteria for neurocysticercosis. Neurology. 2001;57(2):177-183.
    1. Del Brutto OH. Neurocysticercosis. Handb Clin Neurol. 2014;121:1446-2159.
    1. Sharma M, Singh T, Mathew A. Antiepileptic drugs for seizure control in people with neurocysticercosis. Cochrane Database Syst Rev. 2015;3:1550-1555.
    1. Abou-Khalil B, Hemdal P, Privitera MD. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day (-1) in adult patients with refractory epilepsy. Seizure. 2008;12(2):141-149.
    1. García HH, Evans CAW, Nash TE, et al. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev. 2002;15(4):747-756.

Publication types